How pharma companies can ensure essential antimicrobial drugs reach patients who need them most

The article notes that projects across the pipelines of GSK, F2G, Pfizer, Innoviva and Venatorx could save at least 160,000 lives annually by providing much-needed medicines to treat deadly bacterial and fungal drug-resistant infections.

The media coverage emphasises how the report identifies opportunities and recommendations for companies in focus, while also outlining the actionable steps for global stakeholders in antimicrobial R&D to promote widespread adoption of advance access and stewardship planning.

We have a small, but effective, arsenal in the race to combat drug-resistant infections. The difference between us winning or losing this race depends on how companies enable access to people living on the frontlines of drug resistance.

_{Jayasree K. Iyer, CEO, Access to Medicine Foundation}